Login to Your Account

Valeant to Rule Derm Market in $2.6B Medicis Acquisition

By Catherine Shaffer
Staff Writer

Wednesday, September 5, 2012

When J. Michael Pearson, CEO of Valeant Pharmaceuticals International Inc., reached out to Medicis Pharmaceuticals International Inc. to discuss terms for a potential merger, it was the third time the two companies had had such discussions in the last 18 months. In previous talks, the value of Medicis' broad-spectrum tetracycline antibiotic, Solodyn (minocycline), had been a sticking point.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription